DMAC 8-K
DiaMedica Therapeutics Inc. (DMAC)
8-K
2026-05-21
For: 2026-05-20
View Original
Added on
May 21, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 20, 2026
(Exact name of registrant as specified in its charter)
|
|
|
Not Applicable
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
(763 ) 496-5454
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
DiaMedica Therapeutics Inc. (the “Company”) held its 2026 Annual General Meeting of Shareholders (the “2026 AGM”) on May 20, 2026.
At the 2026 AGM, the Company’s shareholders considered four voting proposals, each of which is described in detail in the Company’s definitive proxy statement for the 2026 AGM filed with the United States Securities and Exchange Commission on April 1, 2026.
The final voting results of each voting proposal brought before a vote of the Company’s shareholders at the 2026 AGM are set forth below:
Voting Proposal One - Election of Directors
The seven director nominees, all incumbent directors, proposed by the Board were re-elected to serve as members of the Board until the next annual general meeting of shareholders and until their respective successors are duly elected and qualified based on the following voting results:
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
||||||||||
|
Michael Giuffre, M.D.
|
10,119,610 | 229,027 | 11,180,693 | |||||||||
|
Rick Kuntz, M.D., M.Sc.
|
10,166,733 | 181,904 | 11,180,693 | |||||||||
|
Tanya Lewis
|
10,136,190 | 212,447 | 11,180,693 | |||||||||
|
Daniel O’Connor
|
5,217,758 | 5,130,879 | 11,180,693 | |||||||||
|
James Parsons
|
10,035,604 | 313,033 | 11,180,693 | |||||||||
|
Rick Pauls
|
10,178,755 | 169,882 | 11,180,693 | |||||||||
|
Charles Semba, M.D.
|
10,161,380 | 187,257 | 11,180,693 | |||||||||
Voting Proposal Two – Ratification of Independent Registered Public Accounting Firm
The voting proposal to appoint Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 and authorize the Board to fix the Company’s independent registered public accounting firm’s remuneration was approved based on the following voting results:
|
Votes For
|
Votes Withheld
|
Broker Non-Votes
|
|||||||
| 20,950,404 | 578,926 | 0 | |||||||
Voting Proposal Three – Advisory Vote to Approve of Executive Compensation
The voting proposal to approve, on an advisory (non-binding) basis, the Company’s executive compensation was approved based on the following voting results:
|
Votes For
|
Votes Against
|
Abstain
|
Broker Non-Votes
|
||||||||||
| 9,928,381 | 271,093 | 149,163 | 11,180,693 | ||||||||||
Voting Proposal Four – Amendment and Restatement of the Amended and Restated 2019 Omnibus Incentive Plan
The voting proposal to approve an amendment to the Company’s Amended and Restated 2019 Omnibus Incentive Plan to increase the number of shares available under the plan by 3,500,000 shares was approved based on the following voting results:
|
Votes For
|
Votes Against
|
Abstain
|
Broker Non-Votes
|
||||||||||
| 9,693,413 | 510,487 | 144,737 | 11,180,693 | ||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
DIAMEDICA THERAPEUTICS INC.
|
|||
|
By:
|
/s/ Scott Kellen
|
||
|
Scott Kellen
|
|||
|
Chief Financial Officer and Secretary
|
|||
Date: May 21, 2026